human papillomavirus 9-valent vaccine, recombinant (Gardasil 9) Report issue

Vaccine Approved FDA
AACT

Active Ingredient History

NOW
  • Now
Human papillomavirus (HPV) vaccines are vaccines that prevent infection by certain types of human papillomavirus (HPV). Available HPV vaccines protect against either two, four, or nine types of HPV. All HPV vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer. It is estimated that HPV vaccines may prevent 70% of cervical cancer, 80% of anal cancer, 60% of vaginal cancer, 40% of vulvar cancer, and show more than 90% efficacy in preventing HPV-positive oropharyngeal cancers. They additionally prevent some genital warts, with the quadrivalent and nonavalent vaccines that protect against HPV types HPV-6 and HPV-11 providing greater protection.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Alternative names

9-valent hpv vaccine | gardasil 9 | human papillomavirus 9-valent vaccine, recombinant | human papillomavirus vaccine | human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed) | nonavalent hpv vaccine | recombinant human papillomavirus nonavalent vaccine | v503

Organizations (102)

Research & Development (102)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (49)

Approved Indications (1)


 

Papillomavirus Infections (approved 2014)

Experimental Indications - Clinical Trial Phases 1-4 (49)


 

Acquired Immunodeficiency Syndrome (Phase 3)

Adenocarcinoma in Situ (Phase 3)

Alphapapillomavirus (Phase 4)

Androgens (Phase 3)

Anus Neoplasms (Phase 3)

Carcinoma (Phase 4)

Carcinoma, Basal Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 3)

Cervical Intraepithelial Neoplasia (Phase 4)

Condylomata Acuminata (Phase 3)

COVID-19 (Phase 3)

Dengue (Phase 3)

Drug Evaluation (Phase 4)

Drugs, Investigational (Phase 2)

Genital Diseases (Phase 3)

Head and Neck Neoplasms (Phase 1/Phase 2)

Healthy Volunteers (Phase 3)

Hematopoietic Stem Cell Transplantation (Phase 4)

HIV (Phase 4)

HIV Infections (Phase 4)

Human papillomavirus 16 (Phase 4)

Human Papillomavirus Viruses (Phase 2)

Immunization (Phase 4)

Infections (Phase 4)

Inflammatory Bowel Diseases (Phase 4)

Keratosis, Actinic (Phase 2)

Lung Diseases (Early Phase 1)

Lymphoma (Phase 4)

Measles (Phase 4)

Meningococcal Infections (Phase 3)

Mumps (Phase 4)

Neoplasms (Phase 4)

Neoplasms, Unknown Primary (Phase 1/Phase 2)

Papilloma (Phase 3)

Papillomaviridae (Phase 4)

Papillomavirus Infections (Phase 4)

Papillomavirus Vaccines (Phase 4)

Penile Neoplasms (Phase 1/Phase 2)

Pharmacological and Toxicological Phenomena (Phase 3)

Rubella (Phase 4)

Serology (Phase 4)

Thrombocytopenia (Phase 2)

Transplants (Phase 3)

Uterine Cervical Dysplasia (Phase 4)

Uterine Cervical Neoplasms (Phase 4)

Vaginal Neoplasms (Phase 3)

Vulvar Diseases (Phase 4)

Vulvar Neoplasms (Phase 4)

Warts (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 99
  • # of Trial Organizations: 102

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue